# T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy

> **NCT07300891** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 72 (estimated)

## Conditions studied

- Refractory Solid Cancer Patients Unexposed to Immunotherapy

## Interventions

- **DRUG:** Tisleizumab(BGB-A317)

## Key facts

- **NCT ID:** NCT07300891
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-01-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07300891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07300891, "T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07300891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*